BC Extra | Dec 24, 2019
Company News

Rival suitor could have pressed Synthorx takeout price even higher than winning $2.5B Sanofi bid

A new regulatory filing revealed that Synthorx received a sweeter offer than Sanofi’s $2.5 billion bid after the biotech had already agreed to the French pharma’s proposal. The biotech declined to backtrack on accepting Sanofi’s...
BC Extra | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

Sanofi’s deal for Synthorx shows its continued commitment to building an innovative pipeline in oncology, an area of increasing importance to the pharma, by obtaining both a clinical program targeting IL-2 and a platform it...
BC Extra | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Extra | Nov 28, 2017
Company News

Management Tracks: Synthorx, Vir

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc. (Burlingame, Calif.). Vir Biotechnology Inc. (San Francisco, Calif.) hired Herbert “Skip”...
BC Extra | Aug 22, 2017
Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
BC Extra | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

Scientists led by Caltech’s Raymond Deshaies have published a first-in-class proteasome inhibitor that acts through a distinct mechanism from the multiple myeloma drugs Velcade bortezomib and Kyprolis carfilzomib, which could address patients who don't respond...
BC Extra | Jan 7, 2017
Company News

Management tracks

Genomic profiling company Foundation Medicine Inc. (NASDAQ:FMI) said Troy Cox will replace Michael Pellini as CEO, effective Feb. 6. Pellini will remain chairman. Cox was SVP in bio-oncology sales and marketing at the Genentech Inc....
BioCentury | Aug 15, 2016
Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...
BC Week In Review | Aug 15, 2016
Financial News

Cleave Biosciences completes venture financing

Cleave Biosciences Inc. , Burlingame, Calif.   Business: Cancer   Date completed: 2016-08-08   Type: Venture financing   Raised: $37 million   Investors: Celgene Corp. ; Nextech Invest; Arcus Ventures; 5AM Ventures; Clarus ; New Enterprise...
Items per page:
1 - 10 of 31
BC Extra | Dec 24, 2019
Company News

Rival suitor could have pressed Synthorx takeout price even higher than winning $2.5B Sanofi bid

A new regulatory filing revealed that Synthorx received a sweeter offer than Sanofi’s $2.5 billion bid after the biotech had already agreed to the French pharma’s proposal. The biotech declined to backtrack on accepting Sanofi’s...
BC Extra | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

Sanofi’s deal for Synthorx shows its continued commitment to building an innovative pipeline in oncology, an area of increasing importance to the pharma, by obtaining both a clinical program targeting IL-2 and a platform it...
BC Extra | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Extra | Nov 28, 2017
Company News

Management Tracks: Synthorx, Vir

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc. (Burlingame, Calif.). Vir Biotechnology Inc. (San Francisco, Calif.) hired Herbert “Skip”...
BC Extra | Aug 22, 2017
Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
BC Extra | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

Scientists led by Caltech’s Raymond Deshaies have published a first-in-class proteasome inhibitor that acts through a distinct mechanism from the multiple myeloma drugs Velcade bortezomib and Kyprolis carfilzomib, which could address patients who don't respond...
BC Extra | Jan 7, 2017
Company News

Management tracks

Genomic profiling company Foundation Medicine Inc. (NASDAQ:FMI) said Troy Cox will replace Michael Pellini as CEO, effective Feb. 6. Pellini will remain chairman. Cox was SVP in bio-oncology sales and marketing at the Genentech Inc....
BioCentury | Aug 15, 2016
Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...
BC Week In Review | Aug 15, 2016
Financial News

Cleave Biosciences completes venture financing

Cleave Biosciences Inc. , Burlingame, Calif.   Business: Cancer   Date completed: 2016-08-08   Type: Venture financing   Raised: $37 million   Investors: Celgene Corp. ; Nextech Invest; Arcus Ventures; 5AM Ventures; Clarus ; New Enterprise...
Items per page:
1 - 10 of 31